Razavi Mahmood K, Jaff Michael R, Miller Larry E
From the Heart and Vascular Center, St. Joseph Hospital, Orange, CA (M.K.R.); Fireman Vascular Center, Massachusetts General Hospital, Boston (M.R.J.); and Miller Scientific Consulting, Inc, Asheville, NC (L.E.M.).
Circ Cardiovasc Interv. 2015 Oct;8(10):e002772. doi: 10.1161/CIRCINTERVENTIONS.115.002772.
Endovenous recanalization of iliofemoral stenosis or occlusion with angioplasty and stent placement has been increasingly used to maintain long-term venous patency in patients with iliofemoral venous outflow obstruction. The purpose of this systematic review and meta-analysis was to determine safety and effectiveness of venous stent placement in patients with iliofemoral venous outflow obstruction.
We searched MEDLINE and EMBASE for studies evaluating safety or effectiveness of stent placement in patients with iliofemoral venous outflow obstruction. Data were extracted by disease pathogenesis: nonthrombotic, acute thrombotic, or chronic post-thrombotic. Main outcomes included technical success, periprocedural complications, symptom relief at final follow-up, and primary/secondary patency through 5 years. A total of 37 studies reporting 45 treatment effects (nonthrombotic, 8; acute thrombotic, 19; and chronic post-thrombotic, 18) from 2869 patients (nonthrombotic, 1122; acute thrombotic, 629; and chronic post-thrombotic, 1118) were included. Technical success rates were comparable among groups, ranging from 94% to 96%. Complication rates ranged from 0.3% to 1.1% among groups for major bleeding, from 0.2% to 0.9% for pulmonary embolism, from 0.1% to 0.7% for periprocedural mortality, and from 1.0% to 6.8% for early thrombosis. Patient symptom relief data were reported inconsistently. At 1 year, primary and secondary patency were 96% and 99% for nonthrombotic, 87% and 89% for acute thrombotic, and 79% and 94% for chronic post-thrombotic.
Stent placement for iliofemoral venous outflow obstruction results in high technical success and acceptable complication rates regardless of cause of obstruction.
采用血管成形术和支架置入术对髂股静脉狭窄或闭塞进行静脉再通,越来越多地用于维持髂股静脉流出道梗阻患者的长期静脉通畅。本系统评价和荟萃分析的目的是确定静脉支架置入术治疗髂股静脉流出道梗阻患者的安全性和有效性。
我们检索了MEDLINE和EMBASE数据库,查找评估支架置入术治疗髂股静脉流出道梗阻患者安全性或有效性的研究。根据疾病发病机制提取数据:非血栓形成、急性血栓形成或慢性血栓形成后。主要结局包括技术成功率、围手术期并发症、末次随访时症状缓解情况以及5年的原发性/继发性通畅率。共纳入37项研究,报告了来自2869例患者(非血栓形成组1122例、急性血栓形成组629例、慢性血栓形成后组1118例)的45个治疗效果(非血栓形成组8个、急性血栓形成组19个、慢性血栓形成后组18个)。各组技术成功率相当,范围为94%至96%。各组大出血并发症发生率为0.3%至1.1%,肺栓塞发生率为0.2%至0.9%,围手术期死亡率为0.1%至0.7%,早期血栓形成发生率为1.0%至6.8%。患者症状缓解数据报告不一致。1年时,非血栓形成组原发性和继发性通畅率分别为96%和99%,急性血栓形成组为87%和89%,慢性血栓形成后组为79%和94%。
无论梗阻原因如何,髂股静脉流出道梗阻的支架置入术均能获得较高的技术成功率和可接受的并发症发生率。